secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2023-04-19T23:59:59+00:00
Accession:  0001193125-23-105746
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology reports Phase 1 data for ziftomenib: 30% CR, 35% CRc in R/R NPM1-m AML at RP2D
--------------------------------------------------------------------------------

- In 20 NPM1-m R/R AML patients at 600mg RP2D: CR rate 30%, composite CR (CRc) 35%, ORR 40%.
- Median duration of CRc response 8.2 months; median OS 5.1 months with 8.0 months follow-up.
- Safety: 85% had Grade ≥3 TEAEs; differentiation syndrome (any grade) 20%, Grade 3 DS 5%.
- Patients heavily pretreated: median 2.5 prior therapies, 60% prior venetoclax, 15% prior SCT.
- Registration-directed Phase 2 study of ziftomenib monotherapy in R/R NPM1-m AML now accruing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312523105746/0001193125-23-105746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312523105746/d467874d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-105746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer